Prepares IV drugs on-site and sends nurses to finish the infusion in patients' homes.
At a glance
- Depends onDownstream position: depends on 12 industries, supplies 5
- ScaleMarket cap is above the global median
Prepares IV drugs on-site and sends nurses to finish the infusion in patients' homes.
What this company is and how it runs — written from structure, not news.
Option Care Health takes medications that must be mixed under sterile conditions — things like immunoglobulins and chemotherapy agents — and delivers them as completed infusions inside patients' homes. Because sterile compounding licences are issued by each state for a single physical location, the company has to build a licensed pharmacy and a nursing dispatch hub together in every regional market it serves, and because those mixed medications start degrading within hours of preparation, the nurses completing the infusion must leave from that same building to arrive in time. Revenue is only recognised when a nurse finishes the infusion at the bedside, so if a contamination event forces regulators to shut down a regional compounding facility, both the drug supply and the dispatch hub for that market go dark at once — no pharmacy in a neighbouring state can step in, because the licence boundary makes cross-state substitution illegal regardless of how urgent the need is. Expanding into a new region means obtaining a new licence, building a new facility, and hiring separately credentialled compounding staff before a single patient can be served, so growth is gated by regulatory approvals and local patient density rather than by anything the company controls directly.
How does this company make money?
Medicare Part B and commercial insurers pay a per-infusion fee each time a nurse completes a treatment at home. That single payment bundles several separate charges: the cost of acquiring the drug, a fee for the sterile preparation, the nursing administration time, and a rental charge for the portable infusion pump left in the patient's home.
What makes this company hard to replace?
Physicians build specific medication preparation preferences into their ordering systems, making it disruptive to change providers. Nursing licensure is state-by-state, which slows any competitor trying to build a rival fleet quickly. The prior-authorisation relationships the company holds with major insurers for home infusion coverage take years of claims history to establish, so a new entrant cannot simply replicate them.
What limits this company?
The company can only serve patients in states where it already holds a sterile compounding licence and has a physical facility. It cannot prepare drugs for one state and ship them to another, and it cannot stockpile prepared drugs because they degrade too quickly. Opening a new market means getting a new licence, building or leasing a new facility, and hiring credentialled compounding staff — none of that happens quickly.
What does this company depend on?
The company cannot run without DEA Schedule II-V controlled substance licences for handling chemotherapy agents, FDA-approved specialty biologics supplied by manufacturers like Grifols and CSL Behring, state pharmacy licences for sterile compounding in every jurisdiction it operates, Medicare Part B and commercial insurance prior authorisations that allow home infusion to be covered, and temperature-controlled vehicles and portable infusion pumps used during home delivery.
Who depends on this company?
Oncology practices rely on the company for same-day chemotherapy scheduling at home — if that capacity disappears, they lose that flexibility. Immunodeficiency patients who need weekly IVIG infusions would have to go to hospital outpatient departments instead, adding strain to those facilities. Specialty pharmacies that supply biologics requiring a nurse to administer them would lose their delivery mechanism entirely.
How does this company scale?
Pharmacy operations and nurse scheduling software can be rolled out across new markets using the same standard processes. What cannot be manufactured is a dense enough local patient population to justify building a compounding facility — a market either has enough immunocompromised patients to make a regional operation financially viable, or it does not.
What external forces can significantly affect this company?
More than 60 percent of the company's revenue comes from government payers, so when CMS changes Medicare Part B reimbursement rates, profitability moves directly with it. The nursing shortage left over from pandemic-era workforce exits limits how many infusions the company can actually schedule and complete. FDA approvals of biosimilar versions of expensive biologics like immunoglobulins push down the revenue earned per treatment.
Where is this company structurally vulnerable?
If a contamination or sterility failure hits a regional compounding facility, the state can shut that facility down. Because the pharmacy and the nursing dispatch centre share the same building, both go dark at the same time. No other facility in a neighbouring state can legally step in across the state-licence boundary, and no outside pharmacy can match the preparation-to-delivery speed the integrated model needs. Every patient and every dollar of revenue in that region stops for as long as the shutdown lasts.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Two structural conditions align: (1) a multi-year price band exists where the stock has, on at least two separated occasions, stopped declining and bounced upward, and (2) current price is back inside or just above that zone after a meaningful drawdown from peak. The retest is a real one — the stock is not at a new all-time high being measured as a low.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Equity position looks solid, but the composition deserves a look. Equity ratio is elevated for its industry while goodwill is a large share of total assets and large relative to shareholders equity. The equity cushion sits substantially on acquisition-premium book value rather than on retained earnings or paid-in capital.
Is this company growing?
Three multi-year observations co-occur: revenue increased year-over-year in each of the last three fiscal years, gross profit (absolute level) increased year-over-year in each of the last four fiscal years, and net income was positive in each of the last five fiscal years. The configuration describes growth-and-profitability persistence across three different windows.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph